Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats

World Journal of Gastroenterology

Volumn 15, Issue 15, 2009, Pages 1821-1828

  Zhang, Hai Qiang ^a   Ding, Tomas T ^b   Zhao, Jun Sheng ^c   Yang, Xin ^a   Zhang, Hai Xia ^a   Zhang, Juan Juan ^a   Cui, Yun Long ^d  

^a Qingdao Research Center of Microecology Engineering Technology   (China)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^c People's Hospital   (China)

^d Qingdao East Sea Pharmaceutical Corporation Ltd   (China)

Author keywords

Calcitonin gene related peptide; Clostridium butyricum; Colitis; Interleukin 23; Tumor necrosis factor

Indexed keywords

BUTYRIC ACID; CALCITONIN GENE RELATED PEPTIDE; INTERLEUKIN 23; MESALAZINE; OXAZOLONE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACIDOPHILE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM; BLOOD LEVEL; BODY WEIGHT; CLOSTRIDIUM; CLOSTRIDIUM BUTYRICUM; COLIPHAGE; COLON FLORA; CONTROLLED STUDY; DEFECATION HABIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSOBACTERIUM; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYRATES; CALCITONIN GENE-RELATED PEPTIDE; CLOSTRIDIUM BUTYRICUM; COLITIS; COLON; DISEASE MODELS, ANIMAL; FECES; INTERLEUKIN-23; MESALAMINE; ORGAN SIZE; OXAZOLONE; RANDOM ALLOCATION; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651247141     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1821     Document Type: Article

References (46)

1. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002; 8: 158-161
2. Jiang XL, Quan QZ, Wang ZK. Diagnosis, Clinical types and criteria of effectiveness of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2000 8: 332-334
3. Wang QY, Chen CL, Sun Y, Zhang LL, Liu MJ, Pan LJ. Study the flora analysis result of the ulcertive colitis patients. Zhongguo Weishengtaixue Zazhi 2002; 4: 31-32
4. Ou-yang Q, Liang HL. Ulcertive Colitis. Jixu Yixue Jiaoyu 2006; 20: 30-34
5. Sasakil M, Arakil Y, Tsujikawa T, Andoh A, Fujiyama Y. Intestinal Cell Proliferation and Microflora. Journal of Intestinal Microbiology 2005; 19: 1-8
6. Wu XP, Liu DL, Ling QH. The Therapeutic Application of Clostridium Butyricum on Dextran Sulfate Sodium (DSS) Induced Colitis. Zhonghua Xiaohua Zazhi 2003; 23: 305
7. Araki Y, Andoh A, Takizawa J, Takizawa W, Fujiyama Y. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004; 13: 577-580
8. Araki Y, Andoh A, Fujiyama Y, Takizawa J, Takizawa W, Bamba T. Oral administration of a product derived from Clostridium butyricum in rats. Int J Mol Med 2002; 9: 53-57
9. Araki Y, Andoh A, Fujiyama Y, Takizawa J, Takizawa W, Bamba T. Short-term oral administration of a product derived from a probiotic, Clostridium butyricum induced no pathological effects in rats. Int J Mol Med 2002; 9: 173-177
10. Hu W, Jiang Y, Shen ZX. Efect of Butyrate on Experimental Rat Coiltis Induced with Acetic Acid. Yiyao Daobao 2000; 19: 465-466
11. Song M, Li J, Xia B. Effects of Topical Treatment with 5-Aminoealicylic Acid and Sodium Butyrate on the Expression of Trefoil Factor 3, IL-1β and Nuclear Factor-κB in Trinitrobenzene Sulphonic Acid Induced Colitis in Rats. Zhonghua Xiaohua Zazhi 2005; 25: 598-601
12. Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996; 38: 568-573
13. Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A, Patra S. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2003; 285: G177-G184
14. Lührs H, Gerke T, Müller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-466
15. Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008
16. Friese N, Diop L, Chevalier E, Angel F, Rivière PJ, Dahl SG. Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul Pept 1997; 70: 1-7
17. Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003; 361: 385-391
18. Seybold VS, McCarson KE, Mermelstein PG, Groth RD, Abrahams LG. Calcitonin gene-related peptide regulates expression of neurokinin1 receptors by rat spinal neurons. J Neurosci 2003; 23: 1816-1824
19. Wang WJ, Wang L, Liu Y, Peng SY, Zhang FY, Li P, Wan FC, Cui YL. Therapeutic effects of Ataining on immune ulcerative colitis induced by calf colonic mucosal protein in rats. Shijie Huaren Xiaohua Zazhi 2008; 16: 25-32
20. Xiong DX, Cui YL, Wan FC, Cao YZ, Liang M, Zhu XF, Xiu SJ, Jiang XL, Wei AZ. Anti-diarrhea Effect of Laolining Capsule in Mice with Experimental Diarrhea. Zhongguo Xinyao Zazhi 2002; 11: 319-321
21. Cheng LF, Gan LP, Dong L, Tang DL, Cui YL, Mei W, Wan FC. The Efficacy of Laolining Capsule in Treatment of 70 Patients of Acute and Chronic Diarrhea. Zhongguo Xinyao Zazhi 2002; 11: 317-318
22. Zhang HQ, Li AL, Qiao G, Yang X, Zhang HX, Ma QY, Li XB, Cui YL. Therapeutic effects of A Tai Ning on oxazolone-induced ulcerative colitis in rats. Shijie Huaren Xiaohua Zazhi 2008; 16: 3036-3042
23. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188: 1929-1939
24. Wang X, Ou-yang Q, Luo WJ. Establishment of Oxazolone Induced Mice Colitis Model. Weichang Bingxue 2004; 9: 77-80
25. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005; 315: 196-202
26. Frucht DM. IL-23: a cytokine that acts on memory T cells. Sci STKE 2002; 2002: PE1
27. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725
28. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27: 17-23
29. Puccetti P, Belladonna ML, Grohmann U. Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Crit Rev Immunol 2002; 22: 373-390
30. Izcue A, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008; 28: 559-570
31. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483
32. Baldassano RN, Bradfield JP, Monos DS, Kim CE, Glessner JT, Casalunovo T, Frackelton EC, Otieno FG, Kanterakis S, Shaner JL, Smith RM, Eckert AW, Robinson LJ, Onyiah CC, Abrams DJ, Chiavacci RM, Skraban R, Devoto M, Grant SF, Hakonarson H. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 972-976
33. Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 2007; 13: 511-515
34. Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Davies G, Anderson NH, Gillett PM, McGrogan P, Hassan K, Weaver L, Bisset WM, Mahdi G, Wilson DC, Satsangi J. IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut 2007; 56: 1173-1174
35. Roberts RL, Gearry RB, Hollis-Moffatt JE, Miller AL, Reid J, Abkevich V, Timms KM, Gutin A, Lanchbury JS, Merriman TR, Barclay ML, Kennedy MA. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol 2007; 102: 2754-2761
36. Cummings JR, Ahmad T, Geremia A, Beckly J, Cooney R, Hancock L, Pathan S, Guo C, Cardon LR, Jewell DP. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis 2007; 13: 1063-1068
37. Büning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Bühner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Büttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 1025-1033
38. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998; 290 Suppl: S47-S54
39. Sakaguchi T, Brand S, Reinecker HC. Mucosal barrier and immune mediators. Curr Opin Gastroenterol 2001; 17: 573-577
40. Lu YT, Gao J, Yao GQ. The Experimental Study of the Related Cytokines for in Patients with Ulcertive Colitic. Xiandai Yufang Yixue 2005; 32: 735-736
41. Robinson DR, McNaughton PA, Evans ML, Hicks GA. Characterization of the primary spinal afferent innervation of the mouse colon using retrograde labelling. Neurogastroenterol Motil 2004; 16: 113-124
42. Xing Y, Liu Z, Wang LH, Huang F, Wang HJ, Li ZZ. Butyrate sensitizes the release of substance P and calcitonin gene-related peptide evoked by capsaicin from primary cultured rat dorsal root ganglion neurons. Neuro Endocrinol Lett 2006; 27: 695-701
43. Zhang DR, Dong XX, Bao YF. Analysis of intestinal bacteria of Irritable Bowel Syndrome patients before and after treatment with Clostridium Butyricum Preparation. Zhongguo Weishengtaixue Zazhi 1999; 11: 164-165
44. Zhao X, Ran L, Yang BL, Yao JH, Fu P, Chen ZF, Li ZG. Study of the Effect of Clostridium Butyricum Live Preparation on Intestinal Bacterial Groups. Zhongguo Weishengtaixue Zazhi 1999; 11: 332-333
45. Zhang SB, Cui YL, Wu SE, Li D, Wan FC. Inhibitory Effect of Clostridium Butyricum (CB) on Bacteria. Zhongguo Xingyao Zazhi 2002; 11: 322-324
46. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4: 185-190